



23 December 2024

Our Ref: FOI 408

Dear

**Freedom of Information Act 2000
Information in relation to Treatment of Breast Ovarian and Endometrial
Cancer**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 28 November 2024.

A response to each of the questions raised has been provided by the Unscheduled Care, Medicine & Cancer Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Manning
Information Governance Officer

BREAST CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines, in table 1, in the 3 months between the start of July 2024 to the end of September 2024, or latest 3-month period available?

A1. Please see table 1.

Table 1

| Name of Medicine | No. of Patients Treated |
|---------------------------------------|-------------------------|
| Abemaciclib (Verzenios) | 7 |
| Alpelisib (Piqray) | Nil |
| Elacestrant (Orserdu) | Nil |
| Fulvestrant (fulvestrant or Faslodex) | 8 |
| Inavolisib (Inaqovi) | Nil |
| Palbociclib (Ibrance) | 11 |
| Ribociclib (Kisqali) | 10 |
| Capivasertib (Truqap) | Nil |

Q2. How many patients received for early breast cancer in the 3 months between the start of July 2024 to the end of September 2024, or latest 3-month period for which data are available?

A2. <5 patients received abemaciclib (Verzenios).

Please note that where numbers are 1-4, in line with Trust policy, it is given as <5, to reduce any risk of identification of individual patients.

Q3. How many patients received abemaciclib (Verzenios) with the following treatment, in table 2, intent in the 3 months between the start of July 2024 to the end of Sep 2024, or latest 3-month period for which data are available?

A3. Please see Table 2.

Table 2

| Treatment Intent | No. of Patients Treated |
|--------------------|-------------------------|
| Curative | Nil |
| Palliative | Nil |
| Not known / stated | 7 |

Q4. How many patients were treated with the following medicines, in table 3, in combination with fulvestrant in the 3 months between the start of July 2024 to the end of Sep 2024, or latest 3-month period available?

A4. Please see Table 3.

Table 3

| Name of Combination or Monotherapy | No. of Patients Treated |
|-----------------------------------------------------------------|-------------------------|
| Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex) | Nil |
| Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex) | 7 |
| Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex) | Nil |

Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer, in table 4, in the 3 months between the start of July 2024 to the end of Sep 2024?

A5. Please see Table 4.

Table 4

| Types of Breast Cancer | No. of Patients Treated |
|----------------------------------------------|-------------------------|
| all types of breast cancer | Nil |
| adjuvant treatment for early breast cancer | Nil |
| locally advanced or metastatic breast cancer | Nil |

HER2+VE BREAST CANCER

Q6. How many patients were treated in total with the following products, in table 5, in the 3 months between 1st July 2024 to the end of Sep 2024, or latest 3-months for which data are available?

A6. Please see Table 5.

Table 5

| Name of Medicine | No. of Patients Treated |
|--------------------------------------------------------------------------------|-------------------------|
| Pertuzumab (Perjeta) | Nil |
| Pertuzumab with Trastuzumab (Phesgo) | Nil |
| Trastuzumab (Herceptin, Herzuma, Ontruzant, Trazimera, Zerceptac, trastuzumab) | Nil |
| Trastuzumab Deruxtecan (EnHertu) | Nil |
| Trastuzumab Emtansine (Kadcyla) | Nil |
| Tucatinib (Tukysa) | <5 |

Q7. How many patients received trastuzumab emtansine (Kadcyla) with the following treatment, in table 6, intent in the 3 months between the start of July 2024 to the end of Sep 2024, or latest 3-month period for which data are available?

A7. Please see Table 6.

Table 6

| Treatment Intent | No. of Patients Treated |
|--------------------|-------------------------|
| Curative | Nil |
| Palliative | Nil |
| Not known / stated | Nil |

OVARIAN CANCER and ENDOMETRIAL CANCER

Q8. How many patients were treated in total, regardless of diagnosis, with the following medicines, in table 7, in the 3 months between 1st July 2024 to the end of Sep 2024, or latest 3-months for which data are available?

A8. Please see Table 7.

Table 7

| Name of Medicine | No. of Patients Treated |
|---------------------|-------------------------|
| Niraparib (Zejula) | Nil |
| Rucaparib (Rubraca) | Nil |
| Olaparib (Lynparza) | Nil |

Q9. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines, in table 8, as monotherapy or in combination, in the 3 months between 1st July 2024 to the end of Sep 2024, or latest 3-months for which data are available?

A9. Please see Table 8.

Table 8

| Name of Medicine | No. of Patients Treated |
|---------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| Olaparib in total | Nil |
| Olaparib monotherapy | Nil |
| Olaparib + bevacizumab in combination | Nil |
| Bevacizumab total | Nil |
| Bevacizumab monotherapy | Nil |
| Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin | Nil |

Q10. How many patients were treated for Endometrial Cancer, with the following medicines, in table 9, in the 3 months between 1st July 2024 and 30th September 2024, or latest 3-months for which data are available?

A10. Please see Table 9.

Table 9

| Name of Medicine | No. of Patients Treated |
|--------------------------|--------------------------------|
| Dostarlimab (Jemperli) | Nil |
| Pembrolizumab (Keytruda) | Nil |
| Lenvatinib (Lenvima) | Nil |

Q11. How many patients were treated for Endometrial Cancer, with the following medicines, in table 10, as monotherapy or in combination, in the 3 months between 1st July 2024 and 30th September 2024, or latest 3-months for which data are available?

A11. Please see Table 10.

Table 10

| Name of Medicine | No. of Patients |
|----------------------------------------------|------------------------|
| Dostarlimab monotherapy | Nil |
| Dostarlimab in combination with Chemotherapy | Nil |
| Pembrolizumab monotherapy | Nil |
| Pembrolizumab + Lenvatinib in combination | Nil |
| Lenvatinib monotherapy | Nil |